According to WHO's data in 2005, glaucoma is the second leading cause of blindness after cataracts and the most common irreversible cause of blindness in the world. There are 70 million glaucoma patients worldwide, and it is estimated that the number will reach 80 million by 2020. Blindness caused by glaucoma accounts for 50% of global blindness. China has the largest number (over 24 million) of glaucoma patients in the world, and this number is growing at a rate of more than 1.5 million per year.
Latanoprost is the first FDA approved prostaglandin for intraocular pressure reduction. In 1999, China began importing Latanoprost as a first-line drug in the clinical treatment of glaucoma. In 2004, Latanoprost eye drops developed by Lunan Better were approved for sale, followed by the products of other domestic manufacturers. And there is a continuous rise in the market share of domestic manufacturers. In 2017, Pfizer had the largest market share by sales value, about 39%, a figure that has been declining in recent years.
According to the report, Latanoprost has been growing since it entered China, with its sales value exceeding CNY 40 million in 2017. With an aging population, the incidence of glaucoma is increasing year by year in China. In clinical practice, glaucoma cannot be well treated through operations as cataracts. Therefore, there is a promising market for conservative medications and post-operative medications, and thus a high demand for Latanoprost in China.
- Development environment of Latanoprost in China
- Sales of Latanoprost in China
- Major Latanoprost manufacturers in China
- Retail prices of Latanoprost in China
- Prospects of Chinese Latanoprost market
1 Basic Concepts of Latanoprost
1.1 Indications for Latanoprost
1.2 Development History of Latanoprost in China
1.3 Governmental Approval of Latanoprost in China
2 Investigation on Sales of Latanoprost in China, 2013-2017
2.1 Sales Value of Latanoprost in China
2.1.1 Overall Sales Value
2.1.2 Sales Value in Parts of China
2.2 Sales Value of Latanoprost in China
2.2.1 Overall Sales Volume
2.2.2 Sales Volume in Parts of China
2.3 Sales of Latanoprost in China by Dosage Form
3 Major Latanoprost Manufacturers in China
3.1 Market Competition of Latanoprost in China
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2.1 Enterprise Profile
3.2.2 Sales of Pfizer's Latanoprost in China
3.3.1 Enterprise Profile
3.3.2 Sales of Pharmacia's Latanoprost in China
3.4 Lunan Better Pharmaceutical Co., Ltd.
3.5 China Resources Zizhu Pharmaceutical Co., Ltd.
3.6 Taejoon Pharm
3.7 Chengdu Hengrui Pharmaceutical Co., Ltd.
4 Analysis of Prices of Latanoprost in China, 2017-2018
4.1 Prices of Latanoprost in China
4.1.1 National Average Price
4.1.2 Average Price by Region
4.2 Prices of Major Manufacturers' Latanoprost in China
4.2.1 Pfizer (Xalatan)
4.2.2 Pharmacia (Xalatan)
4.2.3 Lunan Better Pharmaceutical Co., Ltd. (Telijie)
4.2.4 China Resources Zizhu Pharmaceutical Co., Ltd. (Jiankang)
4.2.5 Taejoon Pharm (Ruidaxi)
4.2.6 Chengdu Hengrui Pharmaceutical Co., Ltd. (Shengao)
5 Prospects of Chinese Latanoprost Market, 2018-2022
5.1 Factors Influencing Latanoprost Development in China
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Competition Pattern
Chart Governmental Approval of Latanoprost in China
Chart Sales Value of Latanoprost in China, 2013-2017
Chart Sales Value of Latanoprost in Parts of China, 2013-2017
Chart Sales Volume of Latanoprost in China, 2013-2017
Chart Sales Volume of Latanoprost in Parts of China, 2013-2017
Chart Market Share and Sales Value of Pfizer's Latanoprost in China, 2013-2017
Chart Market Share and Sales Value of Pharmacia's Latanoprost in China, 2013-2017
Chart Market Share and Sales Value of Lunan Better Pharmaceutical Co., Ltd.'s Latanoprost in China, 2013-2017
Chart Prices of Pfizer's Latanoprost in Several Chinese Cities, 2017-2018
Chart Prices of Pharmacia's Latanoprost in Several Chinese Cities, 2017-2018
Chart Prices of Lunan Better Pharmaceutical Co., Ltd.'s Latanoprost in Several Chinese Cities, 2017-2018
Chart Forecast on Sales Value of Latanoprost in China, 2018-2012
- Chengdu Hengrui Pharmaceutical Co., Ltd.
- China Resources Zizhu Pharmaceutical Co., Ltd.
- Lunan Better Pharmaceutical Co., Ltd.
- Taejoon Pharm
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.